Clinical Cancer Research Submission Process
Clinical Cancer Research's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Readiness scan
Before you submit to Clinical Cancer Research, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to Clinical Cancer Research
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- Clinical Cancer Research accepts roughly ~20-30% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach Clinical Cancer Research
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Manuscript preparation |
2. Package | Submission via AACR system |
3. Cover letter | Editorial assessment |
4. Final check | Peer review |
Quick answer: The Clinical Cancer Research submission process runs through AACR SmartSubmit/ScholarOne, but the real screen is translational oncology fit. Editors need to see a credible bridge from mechanism or biomarker evidence to clinical cancer relevance. If that chain is implied rather than demonstrated, fix the package before opening the portal.
What official pages do not answer
AACR's official pages explain the journal, author instructions, and submission mechanics. This official journal guidance does not tell authors whether the manuscript has enough translational oncology maturity to survive the first editorial read. Public summaries mostly answer where to upload, not whether the upload is strategically safe.
This guide separates three process decisions authors often merge: whether SmartSubmit is ready, whether the clinical bridge is visible in the first page, and whether the evidence package justifies Clinical Cancer Research rather than a basic oncology or organ-specific venue.
How this page was created: of the 100 papers our team reviewed when this guide was built, the recurring editorial triage pattern was not portal confusion. It was manuscripts where the abstract promised translational consequence but the first two figures still read as basic cancer biology. We then compared that pattern with recent Manusights pre-submission reviews from authors considering Clinical Cancer Research.
Manusights internal analysis suggests a failure pattern for this page: authors often treat SmartSubmit as the hard part, while editors routinely screen for whether the patient-facing consequence is already visible before peer review.
Source limitations: AACR's public pages do not publish internal triage notes, live desk-rejection reasons, or manuscript-level editorial scoring. Treat the process signals below as pre-submission decision support, not as a guarantee of review or rejection.
For this refresh, we checked AACR journal materials, AACR's 2025 publishing report naming Verify the current Editor-in-Chief on the journal's editorial-team page; the SmartSubmit/ScholarOne submission path at Scholarone source page, and recent Clinical Cancer Research records including 10.1158/1078-0432.CCR-25-1834, 10.1158/1078-0432.CCR-25-3297, and 10.1158/1078-0432.CCR-25-3384.
The live pattern reinforces the process advice here: CCR-ready papers make the patient-facing biomarker, therapeutic, resistance, or diagnostic consequence visible before the editor has to interpret the clinical bridge.
Clinical Cancer Research: Key Metrics
Metric | Value |
|---|---|
Impact Factor (JCR 2024) | 10.2 |
Acceptance rate | ~15% |
Publisher | AACR |
Quick answer: how to submit to Clinical Cancer Research
Method note: This Clinical Cancer Research submission-process guide was updated from AACR journal scope language, AACR author instructions, SmartSubmit routing, Clinical Cancer Research article-type expectations, and Manusights pre-submission review patterns for translational oncology manuscripts. Use this page when you are preparing or interpreting the upload workflow; use the journal profile or desk-rejection page if the core question is fit.
Clinical Cancer Research uses ScholarOne, but the difficult part is not clicking through the system. The difficult part is submitting a file that clearly behaves like a translational oncology paper rather than a basic cancer paper with clinical language added late.
If the manuscript already links mechanism, validation, and patient consequence cleanly, the portal itself is manageable: choose the right article type, upload a disciplined package, make the translational logic explicit in the cover letter, and check that all reporting elements are complete. If the translational consequence is still mostly aspirational, the paper will look weak before reviewers even start.
That is why this page works best as a process and screening guide together. If you are still deciding whether the journal is realistic, start with the Clinical Cancer Research journal profile first. If the fit is real, use this page to make the submission cleaner and faster.
What this page is for
This page is about workflow after submission, not package preparation.
Use it to understand:
- what Clinical Cancer Research editors are deciding in the first days after upload
- why some papers fail before review even when the upload is technically clean
- how to interpret silence, triage, and whether a delay reflects reviewer logistics or a weak editorial read
If you are still deciding whether the journal is the right fit at all, use the fit verdict page. If you still need to strengthen the package before upload, use the Clinical Cancer Research submission guide.
Before you open the submission portal
Before you touch ScholarOne, make sure the package already answers the questions an editor will ask in the first read.
Item | What to confirm before submission | Why it matters |
|---|---|---|
Translational case | The manuscript shows a credible mechanism-to-clinic connection | This journal rejects papers that are still mostly basic biology |
Article type | The file matches the right manuscript category | Misclassified submissions slow the editorial path |
Figures | The clinical or translational consequence is visible in the first key figures | Editors should not have to dig for the patient-facing point |
Human/clinical reporting | Registration, ethics, cohort definitions, and endpoint logic are complete | Missing reporting elements raise trust questions immediately |
Cover letter | The letter states why the paper belongs in Clinical Cancer Research rather than a basic journal | Generic letters waste the strongest part of the editorial pitch |
Supporting files | Supplemental data support the claim instead of rescuing it | If critical validation lives only in supplements, the file feels weaker |
Also check whether the paper is really ready for a translational audience. A manuscript can be good science and still not be ready for this journal. If the patient consequence is mostly interpretive, the portal step is not the problem. The package itself is.
What the first week is really testing
The early stage is not mostly administrative. It is an editorial stress test.
Editors are usually asking:
- does this feel translationally mature enough for Clinical Cancer Research rather than a more basic oncology venue
- is the patient-facing or treatment-facing consequence visible early
- does the evidence package look strong enough for the scope of the claim
- is the manuscript complete enough that reviewers can debate the meaning rather than ask for foundational rescue work
That is why technically clean submissions can still fail quickly.
How to interpret silence or delay
Different kinds of delay usually mean different things:
- very early silence often means internal editorial comparison and scope judgment
- a later quiet period usually means reviewer selection or slow reports
- friction after review often means the translational claim is being weighed against the depth and maturity of the evidence
The useful question is not only how many days have passed. It is what decision the editor is likely making at that stage.
1. Choose the article type honestly
Do not begin by asking what category gives the paper the best chance. Begin by asking what kind of paper this actually is. If it is a full translational story with meaningful validation and oncology consequence, submit it as a full research article. If it is narrower, more focused, or more preliminary, forcing it into the biggest category will not help.
2. Build a manuscript file that makes the translational logic easy to follow
Clinical Cancer Research editors often make an early judgment on whether the manuscript belongs in their lane. The file should make the sequence obvious:
- the oncology problem
- the mechanistic or biomarker logic
- the validation layer
- the patient-facing consequence
If that chain is hard to see, the paper is more likely to be treated as a basic cancer manuscript that should live elsewhere.
3. Upload the core files cleanly
ScholarOne is not where you want to discover that your figures, cover letter, or disclosure details are still in flux. Keep the manuscript, figures, tables, and supplements clearly separated and named. Make sure the version uploaded is the version the authors have actually approved.
4. Use the cover letter to frame the journal fit
The cover letter should not retell the manuscript. It should tell the editor why this paper belongs in a translational oncology journal and why the patient consequence is supported by the data already in the file. If you need a better letter structure, the cover letter guide is a better starting point than a generic template.
5. Review metadata carefully
Clinical studies and translational oncology papers often carry more administrative detail than authors expect. Trial registration, ethics, conflict disclosures, funding, and contributor information should match the manuscript exactly. Metadata inconsistencies slow files and make the submission look less controlled.
6. Expect an editorial screen before the serious review work starts
The earliest decision point is usually whether the manuscript already feels clinically meaningful enough for this journal. That means the first page, first figures, and cover letter do a disproportionate amount of work.
Common mistakes and avoidable delays
These are the mistakes that create the most avoidable trouble:
- The manuscript is still mostly basic cancer biology. Translational wording alone will not carry it.
- The patient consequence is speculative. If the practical implication appears only in the discussion, editors notice.
- Validation is too thin for the ambition of the claim. Biomarker or response claims without enough clinical support create instant skepticism.
- The figures are mechanistically rich but clinically under-explained. Reviewers can miss the translational case if the file does not stage it clearly.
- The cover letter is generic. For this journal, the fit argument matters.
- Administrative details are inconsistent. Trial numbers, ethics statements, author affiliations, and disclosures have to align.
- The paper tries to sound bigger than the evidence. This journal rewards disciplined translational writing, not inflated clinical language.
If you are unsure whether the fit is solid enough, compare this process page with the Clinical Cancer Research journal profile before you submit.
What editors and reviewers will notice first
The first editorial question is usually not whether the biology is interesting. It is whether the manuscript already justifies a translational oncology audience.
Is the oncology consequence visible early?
Editors notice quickly whether the manuscript explains what changes for patients, treatment selection, biomarker interpretation, or resistance logic. If that consequence is buried, the file feels less ready.
Does the validation package support the claim?
Clinical Cancer Research readers are sensitive to overreach. If the conclusion is big, the validation has to be proportionate. Thin cohorts, fragile translational links, or narrow systems weaken the process before reviewers even debate novelty.
Does the writing feel disciplined?
A strong submission feels controlled. It does not oversell. It does not hide weak points in the supplement. It does not use vague translational language as a substitute for evidence.
Can the first page survive scrutiny?
Before you submit, ask:
- Can an editor identify the patient-facing consequence from the abstract and title?
- Is the translational bridge visible in the first figures?
- Does the cover letter explain why the paper belongs here rather than in a basic or organ-specific alternative?
- Would the main claim still feel credible after you remove the most optimistic language?
If the answers are strong, the portal is only the last step. If the answers are weak, the manuscript is not ready for this journal yet.
One last translational screen before upload
Before the corresponding author presses submit, test the paper against the hardest question in this journal family: if the word translational disappeared from the title and cover letter, would the data still force a clinician-facing interpretation?
That question often exposes the last weak point. If the answer depends on future cohorts, future validation, or future therapeutic work, the paper is probably still early. If the answer is already visible in the current figures and tables, the submission is behaving more like a true Clinical Cancer Research package.
One practical way to run that check is to review the package in this order:
- title and abstract
- first two figures
- cover letter
- discussion opening
If those four pieces all point to the same patient-facing conclusion, the file is usually much stronger. If they point in different directions, fix the package before upload and before asking the journal to interpret the story for you.
Another simple check is to ask whether an oncology editor could explain the patient consequence in one sentence after reading only the abstract and first figure legend. If not, the submission package is still asking the journal to do too much interpretive work on your behalf before review even starts.
Before you upload, run your manuscript through a CCR submission readiness check to catch the issues editors filter for on first read.
Readiness check
Run the scan while Clinical Cancer Research's requirements are in front of you.
See how this manuscript scores against Clinical Cancer Research's requirements before you submit.
Submit If
- the abstract states a specific patient-facing, biomarker, therapeutic, or resistance consequence supported by the current data
- the first two figures connect mechanism, model system, and clinical relevance rather than saving the translational argument for the discussion
- the validation layer includes patient-derived, clinical, independent-cohort, or orthogonal evidence proportionate to the main claim
- the cover letter explains why this is Clinical Cancer Research work instead of a basic oncology, cancer biology, or organ-specific oncology submission
Clinical Cancer Research pre-submission process checklist
- confirm the SmartSubmit/ScholarOne article type matches the actual evidence package
- check that trial registration, ethics statements, cohort definitions, endpoints, and disclosures match the manuscript exactly
- read the title, abstract, first two figures, and cover letter as one package and make sure they name the same clinical consequence
- make sure the strongest validation is in the main figures or tables, not hidden in supplemental rescue material
- prepare a fallback journal ladder before upload if the editor reads the paper as too basic or too organ-specific
Think Twice If
- the abstract promises clinical or translational impact, but the main figures only show cell-line or mouse-model biology without patient-facing validation
- the biomarker, treatment-response, or resistance claim relies on one small cohort, one dataset, or one model system without independent confirmation
- the cover letter uses Clinical Cancer Research language, but the first figure sequence would still make sense in a basic cancer biology journal
- the practical implication appears only in the final discussion paragraph rather than in the title, abstract, figures, and endpoint logic
What Pre-Submission Reviews Reveal About Clinical Cancer Research Submissions
For manuscripts targeting Clinical Cancer Research, three submission shapes reliably predict desk-screen failure among the papers we analyze.
Translational wording applied to basic cancer biology
Clinical Cancer Research's author instructions explicitly describe the journal as focused on work "bridging preclinical and clinical cancer research." We see consistent desk rejection of manuscripts where the experimental work is entirely preclinical (cell lines and mouse models) but the cover letter and discussion use translational language about patient implications.
The editors distinguish between papers where the clinical relevance is built into the experimental design (for example, using patient-derived xenografts or clinical biomarker data) and papers where it is rhetorical. If your paper depends on future clinical validation that was not performed, the manuscript is still basic oncology regardless of framing.
Validation layer too thin for the scope of the biomarker or response claim
We observe that manuscripts reporting predictive biomarkers or treatment response signatures are desk-rejected when the validation cohort is small or when the finding is replicated in the same model system rather than an independent one. Clinical Cancer Research readers are specifically evaluating whether a biomarker claim could change clinical practice. A finding validated in one cell line and one mouse model will not meet that bar.
The journal expects at minimum a second independent dataset, and ideally some form of patient sample or clinical data, before a biomarker claim is ready for submission.
Cover letter that promises integration the manuscript has not yet delivered
We find that cover letters for Clinical Cancer Research submissions frequently oversell the translational maturity of the work. Editors at this journal are experienced at reading the gap between what the cover letter describes and what the first two figures actually show. A cover letter describing a "novel therapeutic strategy for treating advanced-stage [tumor type]" when the paper contains only in vitro mechanism data and a small mouse experiment will be read as misrepresenting the manuscript's current state.
SciRev author-reported data confirms Clinical Cancer Research's typically short time to desk-review decision, often within one to two weeks for papers that do not clear the initial screen.
A CCR submission readiness check or the general Clinical Cancer Research submission readiness check can identify whether your translational evidence layer is sufficient for this journal before you enter ScholarOne.
Frequently asked questions
Submit through ScholarOne. Choose the right article type, upload a disciplined package, make the translational logic explicit in the cover letter, and verify all reporting elements are complete. The manuscript must clearly behave like a translational oncology paper.
Clinical Cancer Research editors make triage decisions in the first days after upload. The timeline depends on whether the paper clears the initial check for translational oncology relevance and enters peer review.
Clinical Cancer Research has a meaningful desk rejection rate. The difficult part is submitting a file that clearly behaves like a translational oncology paper rather than a basic cancer paper with clinical language added late. If the translational consequence is mostly aspirational, the paper looks weak before reviewers start.
After upload to ScholarOne, editors assess whether the paper links mechanism, validation, and patient consequence cleanly. Papers that look like basic cancer research dressed in clinical language are triaged early. The translational logic must be explicit, not aspirational.
Sources
Final step
Submitting to Clinical Cancer Research?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Target journal carried over: Clinical Cancer Research
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- Clinical Cancer Research Submission Guide: Requirements & Timeline
- How to Avoid Desk Rejection at Clinical Cancer Research
- Clinical Cancer Research Review Time: What Authors Can Actually Expect
- Clinical Cancer Research 'Under Review': What Each Status Means
- Clinical Cancer Research Acceptance Rate: What Authors Can Use
- Clinical Cancer Research Impact Factor 2026: 10.2, Q1, Rank 29/326